Scientists have warned that shortages of radiopharmaceutical most commonly used in the US for noninvasive diagnosis of cardiac amyloidosis should not delay imaging in at-risk patients, according to a new information statement issued by the American Society of Nuclear Cardiology (ASNC).
Source: dicardiology.comPublished on 2022-06-25
Related news
- Local officials hope national opioid settlement will help curb crisis
- Prism Data Unveils CashScore v3 , the Next Generation of Credit Scoring
- Safety and immunogenicity of 2 - dose heterologous Ad26 . ZEBOV , MVA - BN - Filo Ebola vaccination in healthy and HIV - infected adults : A randomised , placebo - controlled Phase II clinical trial in Africa
- Blog : Pay - as - you - buy insurance – a customer choice - based concept
- Amid Pyrophosphate Shortage , ASNC Issues Statement on How to Use HMDP as an Alternative Radiopharmaceutical in Cardiac Amyloidosis Imaging
- Open data for smallholder weather information services
- Making maritime industries more sustainable and profitable using AI Algorithms – gCaptain